Report cover image

Peptic Ulcer Drugs Market Report and Forecast 2025-2034

Publisher Expert Market Research
Published Jul 28, 2025
Length 350 Pages
SKU # EMAR20319884

Description

The peptic ulcer drugs market attained a value of USD 6.12 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 3.80%, to reach USD 8.89 Billion by 2034.

Peptic Ulcer Drugs Market Overview

Peptic ulcers are characterized by open sores on the lining of the esophagus, stomach, or small intestine. The most common symptom is pain in the upper abdominal region. It is usually caused by the bacterium Helicobacter pylori and long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin. Peptic ulcers affect 1 out of 12 individuals in the United States with 1 in 5 cases associated with the bacterial infection . The rising prevalence of the disease is one of the key factors driving the peptic ulcer drugs market demand and is anticipated to accelerate the growth of the market in the forecast period.

The surge in drug approvals by the health regulatory bodies is expected to further bolster the market growth. In October 2023, the  United States Food and Drug Administration (FDA) approved reformulated vonoprazan tablets for Voquezna Triple Pak and Voquezna Dual Pak to treat Helicobacter pylori infection in adults. Developed by Phathom Pharmaceuticals, a United States-based biopharmaceutical company, these drugs combine antibiotics with vonoprazan, a novel potassium-competitive acid blocker. This new class of acid suppression therapy offers promising H. pylori eradication rates. The company plans to commercially launch it in December 2023 for H. pylori treatment.

The peptic ulcer drugs market share is also expected to experience a significant expansion due to increasing research and development activities backed by robust support from the government. Moreover, the growing geriatric population and advancement in the healthcare system will also boost the market growth.

Peptic Ulcer Drugs Market Segmentation

Peptic Ulcer Drugs Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type
  • Proton Pump Inhibitor
  • H2 Antagonist
  • Antibiotics
  • Antacids
  • Ulcer Protective
Based on the product type, the market covers various therapeutics used in the treatment and management of peptic ulcers. These include proton pump inhibitors, H2 antagonists, antibiotics, antacids, and ulcer protective.

Market Breakup by Disease Indication
  • Gastritis
  • Gastric Ulcer
  • Duodenal Ulcer
  • GERD
  • Others
The peptic ulcer drugs market is divided by disease indication, which includes gastritis, gastric ulcer, duodenal ulcer, and GERD, among others. This segmentation represents the various conditions for which peptic ulcer drugs are prescribed.

Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Peptic ulcer drugs are distributed to the users through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, among others. Each distribution channel offers unique advantages and conveniences for patients seeking access to peptic ulcer medications.

Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  
  • Germany

    •   
  • France

    •   
  • Italy

    •   
  • Spain

    •   
  • United Kingdom
    • Japan
    • India
    The report covers 8 major markets poised to witness significant peptic ulcer drugs market growth in upcoming years. It is divided into the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America dominates the market for peptic ulcer drugs which can be attributed to the rising cases of the disease, along with the growing healthcare expenditure in the region.

    Peptic Ulcer Drugs Market: Competitor Landscape

    The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
    • Orion Corporation
    • Bausch Health Companies Inc.
    • CYTOKINETICS, INC.
    • Aquestive Therapeutics, Inc.
    • Sanofi
    • Covis Pharma
    • Sun Pharmaceuticals Industries Ltd
    • Mitsubishi Tanabe Pharma Corporation
    • BrainStorm Cell Limited
    • ViroMed Co., Ltd
    • Ionis Pharmaceuticals
    • Genervon Biopharmaceuticals, LLC
    • Biogen
    • Orphazyme A/S
    • F. Hoffmann-La Roche Ltd
    Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

    Key Queries Solved in the Peptic Ulcer Drugs Market Report
    • How is the market landscape expected to evolve in coming years?
    • What are the major market trends influencing the market?
    • What are the major drivers, opportunities, and restraints in the market?
    • What will be the effect of each driver, challenge, and opportunity on the market?
    • Which country is poised to lead the market share in the forecast period?
    • Which country is expected to experience expedited growth during the forecast period?
    • What factors contribute to the rising peptic ulcers market demand?
    • What is the incidence and epidemiology of peptic ulcers?
    • What are the different types of peptic ulcer drugs available in the market?
    • What are the latest advancements in peptic ulcer drug research and development, including novel drug candidates and formulations?
    • Which drugs are under clinical trials?
    • What were the major drug approvals used to manage peptic ulcers during the historical period?
    • Which major drug manufacturers are expected to lead the market?
    • What are the key strategies adopted by leading pharmaceutical companies to gain market share?
    • How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics of peptic ulcer drugs?
    *Please Note:* The report will take 5 business days to complete, after order confirmation.

    Table of Contents

    350 Pages
    1 Preface
    1.1 Objectives of the Study
    1.2 Key Assumptions
    1.3 Report Coverage – Key Segmentation and Scope
    1.4 Research Methodology
    2 Executive Summary
    3 Peptic Ulcer Drugs Market Overview – 8 Major Markets
    3.1 Peptic Ulcer Drugs Market Historical Value (2018-2024)
    3.2 Peptic Ulcer Drugs Market Forecast Value (2025-2034)
    4 Peptic Ulcer Overview
    4.1 Guidelines and Stages
    4.2 Pathophysiology
    4.3 Screening and Diagnosis
    4.4 Disease Indication Pathway
    5 Patient Profile
    5.1 Patient Profile Overview
    5.2 Patient Psychology and Emotional Impact Factors
    5.3 Risk Assessment and Disease Indication Success Rate
    6 Peptic Ulcer Epidemiology Scenario and Forecast – 8 Major Markets
    6.1 8MM Epidemiology Scenario Overview (2018-2034)
    6.2 United States Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    6.3 EU-4 and United Kingdom Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    6.3.1 Germany Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    6.3.2 France Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    6.3.3 Italy Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    6.3.4 Spain Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    6.3.5 United Kingdom Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    6.4 Japan Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    6.5 India Peptic Ulcer Epidemiology Scenario and Forecast (2018-2034)
    7 Peptic Ulcer Drugs Market Landscape – 8 Major Markets
    7.1 Peptic Ulcer: Developers Landscape
    7.1.1 Analysis by Year of Establishment
    7.1.2 Analysis by Company Size
    7.1.3 Analysis by Region
    7.2 Peptic Ulcer: Product Landscape
    7.2.1 Analysis by Product Type
    7.2.2 Analysis by Disease Indication
    7.2.3 Analysis by Distribution Channel
    8 Peptic Ulcer Challenges and Unmet Needs
    8.1 Disease Indication Pathway Challenges
    8.2 Compliance and Drop-Out Analysis
    8.3 Awareness and Prevention Gaps
    9 Cost of Disease Indication
    10 Peptic Ulcer Drugs Market Dynamics
    10.1 Market Drivers and Constraints
    10.2 SWOT Analysis
    10.3 Porter’s Five Forces Model
    10.4 Key Demand Indicators
    10.5 Key Price Indicators
    10.6 Industry Events, Initiatives, and Trends
    10.7 Value Chain Analysis
    11 Peptic Ulcer Drugs Market Segmentation (218-2034) - 8 Major Markets
    11.1 Peptic Ulcer Drugs Market (2018-2034) by Product Type
    11.1.1 Market Overview
    11.1.2 Proton Pump Inhibitor
    11.1.3 H2 Antagonist
    11.1.4 Antibiotics
    11.1.5 Antacids
    11.1.6 Ulcer Protective
    11.2 Peptic Ulcer Drugs Market (2018-2034) by Disease Indication
    11.2.1 Market Overview
    11.2.2 Gastritis
    11.2.3 Gastric Ulcer
    11.2.4 Duodenal Ulcer
    11.2.5 GERD
    11.2.6 Others
    11.3 Peptic Ulcer Drugs Market (2018-2034) by Distribution Channel
    11.3.1 Market Overview
    11.3.2 Hospital Pharmacy
    11.3.3 Retail Pharmacy
    11.3.4 Online Pharmacy
    11.3.5 Others
    11.4 Peptic Ulcer Drugs Market (2018-2034) by Region
    11.4.1 Market Overview
    11.4.2 United States
    11.4.3 EU-4 and the United Kingdom
    11.4.3.1 Germany
    11.4.3.2 France
    11.4.3.3 Italy
    11.4.3.4 Spain
    11.4.3.5 United Kingdom
    11.4.4 Japan
    11.4.5 India
    12 United States Peptic Ulcer Drugs Market (218-2034)
    12.1 United States Peptic Ulcer Drugs Market Historical Value (2018-2024)
    12.2 United States Peptic Ulcer Drugs Market Forecast Value (2025-2034)
    12.3 United States Peptic Ulcer Drugs Market (2018-2034) by Product Type
    12.3.1 Market Overview
    12.3.2 Proton Pump Inhibitor
    12.3.3 H2 Antagonist
    12.3.4 Antibiotics
    12.3.5 Antacids
    12.3.6 Ulcer Protective
    12.4 United States Peptic Ulcer Drugs Market (2018-2034) by Disease Indication
    12.4.1 Market Overview
    12.4.2 Gastritis
    12.4.3 Gastric Ulcer
    12.4.4 Duodenal Ulcer
    12.4.5 GERD
    12.4.6 Others
    13 EU-4 and United Kingdom Peptic Ulcer Drugs Market (218-2034)
    13.1 EU-4 and United Kingdom Peptic Ulcer Drugs Market Historical Value (2018-2024)
    13.2 EU-4 and United Kingdom Peptic Ulcer Drugs Market Forecast Value (2025-2034)
    13.3 EU-4 and United Kingdom Peptic Ulcer Drugs Market Overview
    13.4 EU-4 and United Kingdom Peptic Ulcer Drugs Market (2018-2034) by Product Type
    13.4.1 Market Overview
    13.4.2 Proton Pump Inhibitor
    13.4.3 H2 Antagonist
    13.4.4 Antibiotics
    13.4.5 Antacids
    13.4.6 Ulcer Protective
    13.5 EU-4 and United Kingdom Peptic Ulcer Drugs Market (2018-2034) by Disease Indication
    13.5.1 Market Overview
    13.5.2 Gastritis
    13.5.3 Gastric Ulcer
    13.5.4 Duodenal Ulcer
    13.5.5 GERD
    13.5.6 Others
    14 Japan Peptic Ulcer Drugs Market
    14.1 Japan Peptic Ulcer Drugs Market Historical Value (2018-2024)
    14.2 Japan Peptic Ulcer Drugs Market Forecast Value (2025-2034)
    14.3 Japan Peptic Ulcer Drugs Market (2018-2034) by Product Type
    14.3.1 Market Overview
    14.3.2 Proton Pump Inhibitor
    14.3.3 H2 Antagonist
    14.3.4 Antibiotics
    14.3.5 Antacids
    14.3.6 Ulcer Protective
    14.4 Japan Peptic Ulcer Drugs Market (2018-2034) by Disease Indication
    14.4.1 Market Overview
    14.4.2 Gastritis
    14.4.3 Gastric Ulcer
    14.4.4 Duodenal Ulcer
    14.4.5 GERD
    14.4.6 Others
    15 India Peptic Ulcer Drugs Market
    15.1 India Peptic Ulcer Drugs Market (2018-2034) Historical Value (2018-2024)
    15.2 India Peptic Ulcer Drugs Market (2018-2034) Forecast Value (2025-2034)
    15.3 India Peptic Ulcer Drugs Market (2018-2034) by Product Type
    15.3.1 Market Overview
    15.3.2 Proton Pump Inhibitor
    15.3.3 H2 Antagonist
    15.3.4 Antibiotics
    15.3.5 Antacids
    15.3.6 Ulcer Protective
    15.4 India Peptic Ulcer Drugs Market (2018-2034) by Route of Administration
    15.4.1 Market Overview
    15.4.2 Gastritis
    15.4.3 Gastric Ulcer
    15.4.4 Duodenal Ulcer
    15.4.5 GERD
    15.4.6 Others
    16 Regulatory Framework
    16.1 Regulatory Overview
    16.1.1 US FDA
    16.1.2 EU EMA
    16.1.3 Japan PMDA
    16.1.4 Others
    17 Patent Analysis
    17.1 Analysis by Product Type of Patent
    17.2 Analysis by Publication Year
    17.3 Analysis by Issuing Authority
    17.4 Analysis by Patent Age
    17.5 Analysis by CPC Analysis
    17.6 Analysis by Patent Valuation
    17.7 Analysis by Key Players
    18 Grants Analysis
    18.1 Analysis by Year
    18.2 Analysis by Amount Awarded
    18.3 Analysis by Issuing Authority
    18.4 Analysis by Grant Application
    18.5 Analysis by Funding Institute
    18.6 Analysis by NIH Departments
    18.7 Analysis by Recipient Organization
    19 Clinical Trials Analysis
    19.1 Analysis by Trial Registration Year
    19.2 Analysis by Trial Status
    19.3 Analysis by Trial Phase
    19.4 Analysis by Therapeutic Area
    19.5 Analysis by Geography
    20 Funding and Investment Analysis
    20.1 Analysis by Funding Instances
    20.2 Analysis by Product Type of Funding
    20.3 Analysis by Funding Amount
    20.4 Analysis by Leading Players
    20.5 Analysis by Leading Investors
    20.6 Analysis by Geography
    21 Partnership and Collaborations Analysis
    21.1 Analysis by Partnership Instances
    21.2 Analysis by Product Type of Partnership
    21.3 Analysis by Leading Players
    21.4 Analysis by Geography
    22 Supplier Landscape
    22.1 Orion Corporation
    22.1.1 Financial Analysis
    22.1.2 Product Portfolio
    22.1.3 Demographic Reach and Achievements
    22.1.4 Mergers and Acquisitions
    22.1.5 Certifications
    22.2 Bausch Health Companies Inc.
    22.2.1 Financial Analysis
    22.2.2 Product Portfolio
    22.2.3 Demographic Reach and Achievements
    22.2.4 Mergers and Acquisitions
    22.2.5 Certifications
    22.3 CYTOKINETICS, INC.
    22.3.1 Financial Analysis
    22.3.2 Product Portfolio
    22.3.3 Demographic Reach and Achievements
    22.3.4 Mergers and Acquisitions
    22.3.5 Certifications
    22.4 Aquestive Therapeutics, Inc.
    22.4.1 Financial Analysis
    22.4.2 Product Portfolio
    22.4.3 Demographic Reach and Achievements
    22.4.4 Mergers and Acquisitions
    22.4.5 Certifications
    22.5 Sanofi
    22.5.1 Financial Analysis
    22.5.2 Product Portfolio
    22.5.3 Demographic Reach and Achievements
    22.5.4 Mergers and Acquisitions
    22.5.5 Certifications
    22.6 Covis Pharma
    22.6.1 Financial Analysis
    22.6.2 Product Portfolio
    22.6.3 Demographic Reach and Achievements
    22.6.4 Mergers and Acquisitions
    22.6.5 Certifications
    22.7 Sun Pharmaceuticals Industries Ltd
    22.7.1 Financial Analysis
    22.7.2 Product Portfolio
    22.7.3 Demographic Reach and Achievements
    22.7.4 Mergers and Acquisitions
    22.7.5 Certifications
    22.8 Mitsubishi Tanabe Pharma Corporation
    22.8.1 Financial Analysis
    22.8.2 Product Portfolio
    22.8.3 Demographic Reach and Achievements
    22.8.4 Mergers and Acquisitions
    22.8.5 Certifications
    22.9 BrainStorm Cell Limited
    22.9.1 Financial Analysis
    22.9.2 Product Portfolio
    22.9.3 Demographic Reach and Achievements
    22.9.4 Mergers and Acquisitions
    22.9.5 Certifications
    22.10 ViroMed Co., Ltd
    22.10.1 Financial Analysis
    22.10.2 Product Portfolio
    22.10.3 Demographic Reach and Achievements
    22.10.4 Mergers and Acquisitions
    22.10.5 Certifications
    22.11 Ionis Pharmaceuticals
    22.11.1 Financial Analysis
    22.11.2 Product Portfolio
    22.11.3 Demographic Reach and Achievements
    22.11.4 Mergers and Acquisitions
    22.11.5 Certifications
    22.12 Genervon Biopharmaceuticals, LLC
    22.12.1 Financial Analysis
    22.12.2 Product Portfolio
    22.12.3 Demographic Reach and Achievements
    22.12.4 Mergers and Acquisitions
    22.12.5 Certifications
    22.13 Biogen
    22.13.1 Financial Analysis
    22.13.2 Product Portfolio
    22.13.3 Demographic Reach and Achievements
    22.13.4 Mergers and Acquisitions
    22.13.5 Certifications
    22.14 Orphazyme A/S
    22.14.1 Financial Analysis
    22.14.2 Product Portfolio
    22.14.3 Demographic Reach and Achievements
    22.14.4 Mergers and Acquisitions
    22.14.5 Certifications
    22.15 F. Hoffmann-La Roche Ltd
    22.15.1 Financial Analysis
    22.15.2 Product Portfolio
    22.15.3 Demographic Reach and Achievements
    22.15.4 Mergers and Acquisitions
    22.15.5 Certifications
    23 Peptic Ulcer Disease Indication Drugs - Distribution Model (Additional Insight)
    23.1 Overview
    23.2 Potential Distributors
    23.3 Key Parameters for Distribution Partner Assessment
    24 Key Opinion Leaders (KOL) Insights (Additional Insight)
    25 Company Competitiveness Analysis (Additional Insight)
    25.1 Very Small Companies
    25.2 Small Companies
    25.3 Mid-Sized Companies
    25.4 Large Companies
    25.5 Very Large Companies
    26 Payment Methods (Additional Insight)
    26.1 Government Funded
    26.2 Private Insurance
    26.3 Out-of-Pocket

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us